The evidence for this entry is really two separate bodies of work, one for Semax and one for Selank, both largely Russian. There are no dedicated trials of the combination. This page summarizes that situation.
Overview
To appraise the Semax + Selank blend fairly, it helps to recognize that there is no single "Semax + Selank" evidence base. Instead there are two component literatures, each with its own strengths and gaps.
- Semax research centers on cognition and neuroprotection.
- Selank research centers on anxiety.
- Both are largely Russian and not widely replicated internationally.
Two separate literatures
Semax and Selank have both seen clinical use in Russia, which means their component literatures are more developed than those of many obscure research peptides. Even so, independent international replication is limited for each.
- Semax has been studied for cognitive and neuroprotective endpoints.
- Selank has been studied for anxiety-related endpoints.
- For both, mainstream, non-Russian confirmatory trials are sparse.
The missing combination data
The decisive point for this product is what is absent: dedicated studies of Semax and Selank used together. Every statement about the blend's combined effect is therefore an extrapolation from single-agent work.
- No combination trials means no direct evidence of synergy or safety together.
- Extrapolating from two literatures is weaker than testing the actual product.
- The extrapolation should always be made explicit rather than hidden.
How to read this evidence
A fair reading of the Semax + Selank evidence:
- Treat component claims as hypothesized and combination claims as doubly so.
- Remember neither component is FDA-approved.
- Distinguish Russian clinical use from internationally replicated proof.
- Do not treat two single-agent literatures as evidence for the blend.
In short, the components are better studied than many research peptides, but the combination itself remains unproven.